Healthtech company Ro today announced the acquisition of femtech company Modern Fertility, a high-growth reproductive health company focused on addressing gaps in women’s healthcare through fertility testing, research, education, and community. Since 2017, Modern Fertility has empowered people with ovaries nationwide to play a more active role in their health and build the lives they want on their own terms. The acquisition represents…
Femasys, a biomedical company focused on women’s health, has reportedly filed for a $40.25M IPO and will list on the Nasdaq under the ticker “FEMY”. We are a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. Our mission is to provide women worldwide with superior minimally-invasive, non-surgical product…
Audax has announced that it has signed a definitive agreement to sell Axia Women’s Health to Partners Group on behalf of its clients. Axia Women’s Health is a women’s healthcare provider in the U.S. The Company is headquartered in Voorhees, New Jersey, and provides a highly integrated platform of non-clinical business and administrative support services such as accounting, HR, insurance, IT, and…
Aspira, a bio-analytical based women’s health company focused on gynecologic disease, has announced plans to raise $45 million through a public offering of common stock. The company intends to use the net proceeds from the offering for sales and marketing, working capital and other general corporate purposes, including investing in additional key strategic hires, product portfolio expansion and research and development. Aspira…
U.K.based personal hygiene company Reckitt Benckiser has announced the acquisition of intimate care brand Queen V last week. Queen V has been around since 2018 and offers a selection of vaginal hygiene and health products. The company was backed by Lightspeed Venture Partners, and has sold products at Walmart and CVS. Queen V will now join Reckitt Benckiser’s health global business, that’s…
Hologic announced today that it has agreed to acquire Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments. “Acquiring Biotheranostics enables us to jump-start our entry into a large, fast-growing oncology adjacency that fits perfectly with our broader corporate focus and passion…
